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 1 800 and 7.1 (4.1–10.2; p = 0.005) for scores  1 1,600.  Conclu-
sions: The additional determination of PAT increases the pre-
dictive power of CAC for future cardiovascular events. PAT 
might therefore be used as a further parameter for risk strat-
ification.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Coronary artery disease (CAD) is still the leading 
cause of death in western industrialized countries. A 
more effective and patient-centered prophylaxis is need-
ed to decrease CAD-associated morbidity and mortality. 
To establish an effective individual prophylaxis of future 
cardiovascular events, reliable risk stratification is cru-
cial.
 Coronary artery calcification (CAC) has shown to be 
a highly specific marker of coronary atherosclerosis and 
its extent is directly related to the atherosclerotic plaque 
burden  [1] . Several clinical studies identified CAC as a 
valuable predictor for the risk of subsequent cardiovascu-
lar events in the context of patient screening and in study 
groups with cardiovascular risk factors  [2–5] . Various 
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 Abstract 
 Objectives: Pericardial adipose tissue (PAT) is associated 
with coronary artery plaque accumulation and the incidence 
of coronary heart disease. We evaluated the possible incre-
mental prognostic value of PAT for future cardiovascular 
events.  Methods: 145 patients (94 males, age 60  8 10 years) 
with stable coronary artery disease underwent coronary ar-
tery calcification (CAC) scanning in a multislice CT scanner, 
and the volume of pericardial fat was measured. Mean ob-
servation time was 5.4 years.  Results: 34 patients experi-
enced a severe cardiac event. They had a significantly higher 
CAC score (1,708  8 2,269 vs. 538  8 1,150, p  ! 0.01), and the 
CAC score was highly correlated with the relative risk of a fu-
ture cardiac event: 2.4 (1.8–3.7; p = 0.01) for scores  1 400, 3.5 
(1.9–5.4; p = 0.007) for scores  1 800 and 5.9 (3.7–7.8; p = 0.005) 
for scores  1 1,600. When additionally a PAT volume  1 200 cm 3 
was determined, there was a significant increase in the event 
rate and relative risk. We calculated a relative risk of 2.9 (1.9–
4.2; p = 0.01) for scores  1 400, 4.0 (2.1–5.0; p = 0.006) for scores 
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studies indicate that CAC has a significantly higher diag-
nostic accuracy in predicting cardiovascular events and 
offers the possibility of a more individual risk assessment 
compared to conventional risk stratification scores (i.e. 
Framingham and UK Prospective Diabetes Study risk 
scores  [6–8] ).
 Visceral adipose tissue plays an important role in the 
development of the metabolic syndrome and is an impor-
tant risk factor for CAD  [9, 10] . Pericardial adipose tissue 
(PAT) is a local visceral fat depot. Due to its close proxim-
ity to the coronary arteries, it may serve as a source of 
inflammatory cytokines and cells that locally enhance 
systemic pro-atherogenic effects via outside-to-inside 
signaling  [11, 12] . PAT may therefore be a parameter in-
dicating an unfavorable cardiometabolic state and may 
be used for risk stratification. In a previous study, we 
demonstrated that elevated PAT volumes are associated 
with coronary atherosclerosis and an increased number 
of diseased coronary segments  [13] . It is still unclear 
whether PAT possesses a predictive value for future car-
diovascular events similar to CAC.
 Both parameters, CAC and PAT, can be easily assessed 
non-invasively by multi-slice CT without the administra-
tion of contrast agents. PAT volume and CAC score can 
be determined by analyzing the same data set, thus we 
sought to evaluate the incremental prognostic value of 
PAT and CAC over CAC alone for predicting the occur-
rence of cardiac events and long-term survival of patients 
with stable CAD.
 Patients and Methods 
 Patients 
 Patients with stable CAD (n = 145, 94 males, age 60  8 10 
years), defined by the criterion of at least one coronary artery ste-
nosis ( 1 50% in coronary angiography) and/or prior myocardial 
infarction (MI; 29 patients; 22%) underwent CAC scanning be-
tween January 2000 and April 2006. Of 145 patients, 95 where 
symptomatic at baseline, and 47 had prior stent implantation. Pa-
tients were recruited during their follow-up visits according to 
routine protocols or in the event that new symptoms appeared. 
All patients gave written informed consent to undergo multislice 
CT for CAC scanning according to a protocol that was approved 
by the local clinical institutional review board. Patients and treat-
ing physicians were unaware of CAC results, so that an influence 
of clinical treatment could be excluded.
 Patients with acute coronary syndrome, advanced ischemic 
cardiomyopathy, defined as reduced left ventricular ejection frac-
tion ( ! 35%) and patients who had undergone coronary artery by-
pass grafting were excluded.
 Further patient characteristics are shown in  table 1 .
 Risk Factors 
 The diagnosis of diabetes mellitus was confirmed in all pa-
tients by glucose determination in the fasting state as described 
by the definition of the World Health Organization  [14] . In every 
patient, arterial blood pressure (three times after 10 min of rest), 
and levels of LDL and HDL cholesterol, and triglycerides were de-
termined in the fasting state in our hospital. Arterial hyperten-
sion was defined as systolic blood pressure  1 140 mm Hg or dia-
stolic blood pressure  1 90 mm Hg. Family history was defined as 
coronary heart disease in male first-degree relatives  ! 55 years 
and coronary heart disease in female first-degree relatives  ! 65 
years. Smoking was defined as current smoking or a lifetime his-
tory of having smoked within the last 5 years.
 Coronary Artery Calcium Scanning 
 CAC scanning was performed using a Siemens multislice CT 
scanner (Somatom Sensation 4 or 16; Siemens Medical Solutions, 
Forchheim, Germany) in the high-resolution mode. ECG-trig-
gered scans of 100-ms duration were acquired at 80% of the R-R 
interval during one end-inspiratory breath-holding period. A to-
tal of 40.3-mm-thick slices were obtained covering the whole 
heart. Coronary calcifications were automatically defined as le-
sions with a density  1 130 HU in  1 4 adjacent pixels. For quantifi-
Table 1.  Baseline characteristics of the study patients
Males 94 (65)
Females 51 (35)
Age, years (range) 60810 (29–87)
Hypertension 108 (74)
Diabetes 25 (17)
Smokers 64 (44)
Family history of premature CAD 49 (38)
Hypercholesterolemia 90 (62)
Risk factors
None 8 (0.5)
One 27 (19)
Two 67 (46)
Three 36 (25)
Four 7 (0.5)
Risk factors per patient, n 2.281.1
Pericardial fat, cm3 (range) 2408110 (72–789)
Coronary artery calcium score (range) 84781,555 (0–9,586)
CAD history
One-vessel disease 46 (33)
Two-vessel disease 69 (45.5)
Three-vessel disease 30 (21)
Therapy
Acetylsalicylic acid 139 (95)
Clopidogrel 44 (30)
Statin 119 (82)
ACEI 122 (84)
Angiotensin inhibitor 17 (12)
-Blocker 115 (79)
D ata are means 8 SD or numbers (%). ACEI = Angiotensin-
converting enzyme inhibitor.
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cation of coronary calcium, the Agatston score was calculated, 
which constitutes the product of the surface area of the lesion and 
a weighting factor ranging from 1 to 4. The weighting factor was 
based on the peak density of the lesion  [15] . Coronary segments 
with stents were excluded from quantifications.
 Pericardial Fat Assessment Protocol 
 CT measurements of pericardial fat were performed as de-
scribed by our group previously  [11] . The same images used for 
the analysis of CAC scores were also used to measure PAT. The 
volume of pericardial fat was measured in cubic centimeters using 
the volume analysis software tool of our cardiac workstation 
(Leonardo; Siemens Medical Solutions, Forchheim, Germany).
 Pericardial fat was defined as epicardial fat plus paracardial 
fat. Epicardial fat was defined as any adipose tissue located with-
in the pericardium; paracardial fat was defined as any adipose 
tissue situated on the external surface of the parietal pericardium. 
The superior cutoff point in the axial slices was the bifurcation of 
the pulmonary artery. Inferiorly, the volume analyzed was seg-
mented up to the intraabdominal adipose tissue. The anterior 
border was defined by the anterior chest wall and the posterior 
border by the esophagus and the descending aorta. The region of 
interest containing the heart and the surrounding adipose tissue 
was assessed by manual tracing of the axial slices. The observer 
had simultaneous access to the coronal images.
 After the segmentation of the heart and surrounding adipose 
tissue from the remainder of the thorax, a threshold of –250 to –30 
HU was applied to isolate the adipose tissue (fat)-containing vox-
els. The adipose tissue voxels were then summed to obtain adipose 
tissue volume (in cm 3 ;  fig. 1 ). PAT measurements were performed 
by two independent investigators who were unaware of CAC 
scores.
 Patient Outcomes 
 Patient outcomes were recorded by telephone interviews by an 
investigator blinded to the patients’ test results. Patients were fol-
lowed for the occurrence of severe cardiac events, defined as ei-
ther cardiac death (CD), confirmed by a review of death certifi-
cates and hospital charts or physician s’ records, or MI, defined 
by typical ECG findings, myocardial enzyme elevations and typ-
ical symptoms. Coronary revascularization was confirmed by a 
review of hospital charts or physician’s records. The decision to 
perform coronary revascularization was made on the basis of 
clinical angiographic findings of stenosis  1 50% or the occurrence 
of symptoms in conjunction with significant SPECT myocardial 
perfusion imaging under stress conditions. Patients with non-CD 
were excluded from the study.
 Statistical Analysis 
 Categorical variables are presented with absolute and relative 
frequencies; continuous variables are presented as means  8 SD. 
For between-group comparisons, unpaired Student’s t tests were 
used for parametric data, and Mann-Whitney tests for nonpara-
metric data. Where appropriate, a Pearson 2 or Fisher’s exact test 
was performed to determine significant differences.
 The end of follow-up was defined as either the date of a severe 
cardiac event or the end of the study period. For univariate anal-
ysis of time-to-event data, Kaplan-Meier survival curves, includ-
ing log rank tests, were constructed. Non-CD were treated as 
right-censored data points in the Kaplan-Meier plots. The multi-
variate Cox proportional hazard model was used to obtain hazard 
ratio estimates and 95% confidence intervals for CAC score and 
PAT adjusted for sex, age and coronary risk factors, including hy-
pertension, hypercholesterolemia and diabetes. Annualized event 
rates were calculated on the basis of events per patient per year. 
Statistical software (SAS, version 9.1; SAS Institute, Cary, N.C., 
USA) was used to perform the analyses. Values of p  ! 0.05 were 
considered statistically significant.
 Results 
 PAT Volume and CAC Scores 
 CAC scanning could be performed and adequate im-
age quality for evaluation of CAC could be obtained in all 
145 patients. The PAT volume could be determined in all 
145 study patients. There was no significant difference in 
mean age between men (58.3  8 10.1 years) and women 
(61.3  8 10.3 years). Image analysis for PAT as well as for 
CAC was performed by two experienced investigators 
(M.G. and A.B.). Interobserver variability was assessed 
a b
 Fig. 1.  a Patient with a PAT volume  1 200 
cm2 and a CAC score  1 400 cm 3 who suf-
fered a severe cardiac event during the fol-
low-up.  b Patient with a PAT volume  ! 100 
cm 2 and a CAC score  ! 400 without any se-
vere cardiac event during the follow-up. 
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using Bland/Altman analysis. Interobserver variability of 
PAT volume and CAC measurements was low with 6 and 
4%, respectively.
 Mean CAC score was 847  8 1,555 (males 1,152  8 
1,709 and females 692  8 1,381). Patients with cardiovas-
cular events showed a significantly higher CAC score 
compared to event-free patients (1,708  8 2,269 vs. 538  8 
1,150, p  ! 0.001).
 Mean PAT volume was 240  8 110 cm 3 .  Figure 2 shows 
the distribution of PAT volume in the different CAC sub-
groups. In patients with CAC scores  1 1,600, the fraction 
of patients with a PAT volume  ! 200 cm 3 was significant-
ly lower compared to patients with CAC scores  ^  400. 
The percentage of patients with a PAT volume  1 400 cm 3 
increased from 1% for patients with a CAC score of 0, to 
20% for patients with a CAC score  1 1,600. However, the 
range of PAT volumes in the different CAC score sub-
groups showed no significant difference: in all CAC sub-
groups, patients with PAT volumes  ! 200 but also  1 400 
cm 3 could be found.
 Outcome, Events and Survival Analysis 
 The median follow-up time was 5.4 years (range 3–8 
years). Two patients were excluded from the analysis due 
to death of non-cardiac cause. Ten patients (6.9%) suf-
fered a severe cardiac event (4 CD and 6 MI) and in 22 
patients (15.3%) a coronary revascularization had to be 
performed. In total, 32 of 143 patients (22.3%) had severe 
cardiac events or underwent coronary revascularization 
during the follow-up period. Event rates of the different 
subgroups are shown in  table 2 .
 Traditional cardiovascular risk factors such as age  1 65 
years, hypertension, hypercholesterolemia or diabetes 
mellitus could not be identified as significant risk factors 
for future cardiovascular events ( table 3 ). The Cox pro-
portional hazard model, which was adjusted for age, sex 
0
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 Fig. 2. Bar graphs show the distribution of 
PAT volumes in different CAC subgroups. 
Data below bars are numbers of patients 
and mean PAT volumes of different CAC 
subgroups. 
Table 2.  Frequency of severe cardiac events during the long-term 
follow-up 
Group Patients
n (%)
Severe cardiac
events, n (%)
All patients 143 32
CAC score
0–400 90 (62.9) 10 (31.2)
401–800 12 (8.3) 6 (18.7)
901–1,600 15 (10.4) 5 (15.6)
>1,600 26 (18.1) 11 (34.3)
PAT volume, cm3
0–200 55 (38.4) 8 (25)
200–400 77 (53.8) 24 (75)
400–600 10 (6.9) 0
>600 1 (0.6) 0
CAC score with PAT <200 cm3
0–400 41 (28.6) 2 (6.2)
401–800 6 (4.1) 3 (9.3)
801–1,600 5 (3.4) 1 (3.1)
>1,600  3 (2) 2 (6.2)
CAC score with PAT >200 cm3
0–400 49 (34.2) 8 (25)
401–800 6 (4.1) 3 (9.3)
801–1,600 10 (6.9) 5 (15.6)
>1,600 23 (16) 8 (25)
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and coronary risk factors, was used to identify CAC score 
and PAT volume as the only independent predictors for 
future severe cardiovascular events in this high-risk pa-
tient population, in both uni- and multivariate analyses. 
In univariate analysis, CAC score  1 400 (odds ratio 2.6;
p = 0.02) and PAT  1 200 cm 3 (odds ratio 2.1; p = 0.017) 
were identified as risk factors for future cardiovascular 
events in our study group. The odds ratio for future severe 
cardiovascular events for a CAC score  1 400 in the mul-
tivariate analysis was 2.4 (1.8–3.7; p = 0.01) and increased 
in parallel with the CAC score: 3.5 (1.9–5.4; p = 0.007) for 
CAC scores  1 800 and 5.9 (3.7–7.8; p = 0.005) for CAC 
scores  1 1,600.
 The risk for future cardiovascular events in the multi-
variate analysis for patients with PAT volume  1 200 cm 3 
was 2.1 (1.4–3.2; p = 0.01). In contrast to the CAC score, 
where a further increase in risk with higher CAC scores 
was demonstrated, the risk for future cardiovascular 
events did not further increase with increasing PAT vol-
umes (2.2 for PAT scores  1 400 cm 3 and 2.5 for PAT scores 
 1 600 cm 3 ).
 The CAC score was the most important risk factor for 
future cardiovascular events and the risk increased in 
parallel with the CAC scores. Nevertheless, a PAT volume 
 1 200 cm 3 as a concomitant risk factor offered incremen-
tal prognostic value over the CAC score alone. When 
used in combination with an elevated CAC score, we cal-
culated a further increased risk for future events (2.4 vs. 
2.9 for CAC scores  1 400, 3.5 vs. 4.0 for CAC scores  1 800 
and 5.9 vs. 7.1 for CAC scores  1 1,600;  table 3 ).
 Kaplan-Meier survival curves showed an increased 
risk of cardiovascular events for patients with a CAC 
score  1 400 in comparison to patients with a score  ! 400 
( fig. 3 a). In the subgroup of patients with a score  1 400 and 
a PAT volume  1 200 cm 3 , there was a significantly higher 
risk of cardiovascular events compared to those with a 
PAT volume  ! 200 cm 3 ( fig. 3 b).
 Discussion 
 The aim of this pilot study was to evaluate if PAT in-
creases the prognostic value of CAC for future cardiovas-
cular events.
 Our study population consisted of patients with 
known CAD, therefore the clinical impact of an intensi-
fied risk stratification by PAT determination is limited. 
On the other hand, we managed to archive an adequate 
Table 3.  Analysis of patient characteristics and imaging scores as predictors of clinical outcome
Variable Severe cardiac events, univariate 
analysis
S evere cardiac events, multivariate 
analysis
hazard ratio p value hazard ratio p value 
Hypertension 1.1 (0.8–1.3) NS
Hypercholesterolemia 1.3 (0.8–1.6) NS
Diabetes 1.6 (1.1–1.8) NS
Age >65 years 1.1 (0.7–1.3) NS
CAC score >400 2.6 (2.0–3.3) 0.02
PAT volume >200 2.1 (1.6–3.0) 0.017
CAC score >400 2.4 (1.8–3.7) 0.01
CAC score >800 3.5 (1.9–5.4) 0.007
CAC score >1,600 5.9 (3.7–7.8) 0.005
PAT volume >200 2.1 (1.4–3.2) 0.01
PAT volume >400 2.2 (1.5–3.4) 0.01
PAT volume >600 2.5 (1.6–3.9) 0.009
CAC score >400 and PAT >200 2.9 (1.9–4.2) 0.009
CAC score >400 and PAT >400 3.0 (1.9–4.5) 0.009
CAC score >400 and PAT >600 3.0 (1.9–4.9) 0.009
CAC score >400 and PAT >200 2.9 (1.9–4.2) 0.01
CAC score >800 and PAT >200 4.0 (2.1–5.0) 0.006
CAC score >1,600 and PAT >200 7.1 (4.1–10.2) 0.005
Dat a in parentheses are 95% confidence intervals. NS = Not significant. PAT in cm3.
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event rate to evaluate the predictive value of PAT. The 
event rate in our study cohort (22.3%) is comparable to 
the event rate in other studies investigating patients with 
known CAD and a high risk for future cardiovascular 
events  [16] .
 CAC is a well-established risk marker for future car-
diovascular events. In this study, patients with cardiovas-
cular events also had a significantly higher CAC score 
compared to those without events. CAC was the strongest 
risk factor for future cardiovascular events compared to 
classic cardiovascular risk factors such as hypercholester-
olemia, hypertension, diabetes, smoking or a family his-
tory of CAD. These findings are consistent with those of 
several other studies that have shown that CAC is supe-
rior to classic cardiovascular risk factors or other risk 
scores like the Framingham risk score or the ATB III 
score, not only in asymptomatic patients but also in pa-
tients with known CAD  [7, 8, 17–19] . The risk for future 
cardiovascular events increased continuously with the 
amount of CAC  [5, 20] . The relative risk increased from 
2.4 for patients with scores from 400 to 800 to 3.5 for 
scores from 801 to 1,600 and 5.9 for scores  1 1,600. Addi-
tionally, we found a high negative predictive power of up 
to 100%. This was also shown in several other studies  [4, 
6, 21] . Correspondingly, the proportion of patients with 
an event-free survival was significantly higher in patients 
with scores  ! 400 ( fig. 3 a). The conventional cardiovascu-
lar risk factors age, hypercholesterolemia, hypertension 
or diabetes did not help to stratify the cardiovascular risk 
within this high-risk population ( table 3 ).
 Being a visceral fat depot, PAT produces a large amount 
of proinflammatory chemokines like TNF-  , IL-6, free 
fatty acids or plasminogen activator inhibitor-1, which 
are involved in atherosclerosis and thrombosis. Adipo-
nectin, which has anti-atherosclerotic properties, shows 
an inverse correlation with PAT  [12] . Several studies dem-
onstrated that PAT is related to cardiovascular risk fac-
tors as well as to the metabolic syndrome. Furthermore, 
PAT is related to CAD  [22, 23] . In addition, we recently 
demonstrated that PAT reflects the extent of coronary 
atherosclerosis and the individual plaque burden. The 
PAT volume correlated with the relative risk of CAD and 
the number of atherosclerotic lesions  [13] . Due to these 
findings, we hypothesize that elevated PAT indicates an 
unfavorable metabolic status and might be used as an ad-
ditional risk factor for future cardiovascular events. Sim-
ilar findings were reported in patients without known 
CAD by Ding et al.  [24]  and Cheng et al.  [25] .
 As indicated by the low interobserver variability, PAT 
volume could be determined very reliably. The determi-
nation of PAT volume itself can be performed easily using 
the same data set acquired for CAC screening without ad-
ditional radiation exposure.
 In our patient population, PAT volume increased with 
increasing CAC score ( fig. 2 ). Nevertheless, patients with 
a PAT volume  1 400 cm 3 and patients with a PAT volume 
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Ev
en
t-
fr
ee
 s
ur
vi
va
l
0 20 40 60
Time (months)a
80 100 120
70 CAC <400
CAC >400
80
*
90
100
60
Ev
en
t-
fr
ee
 s
ur
vi
va
l
0 20 40 60
Time (months)b
80 100 120
70 CAC >400 and PAT <200 cm3
*
CAC >400 and PAT >200 cm3
80
90
100
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 ! 200 cm 3 could be found in all CAC subgroups. This in-
dicates that PAT can be considered an independent risk 
factor that might offer additional information to risk 
stratification.
 Corresponding results were found in the analysis of 
cardiovascular events: a PAT volume  1 200 cm 3 was as-
sociated with an increased relative risk (2.1; p = 0.01) in-
dependent of concomitant risk factors; a further increase 
in the relative risk for patients with higher PAT volumes 
could not be observed. These finding comply with the 
results of Ding et al.  [24] , who recently demonstrated an 
association between PAT and the incidence of coronary 
heart disease.
 Using PAT volume  1 200 cm 3 and CAC score as a com-
bined risk factor, we could increase the predictive power 
in comparison to CAC alone. PAT volume  1 200 cm 3 de-
termined in addition to the CAC score significantly in-
creased the relative risk for future cardiovascular events: 
2.9 for scores of 400–800, 4.0 for scores of 801–1,600 and 
7.1 for scores  1 1,601. Thus, the additional determination 
of PAT increased the predictive power of CAC for future 
cardiovascular events. The combination of these two pa-
rameters may provide improved risk stratification.
 Limitations 
 The study population was relatively small and consist-
ed of patients with known cardiovascular diseases and 
with a high risk for future cardiovascular events. Our 
study population cannot be considered as an unselected 
population and our results may not be applicable to as-
ymptomatic patients without known obstructive CAD. 
Because of our small study population we cannot exclude 
that small but significant associations between PAT, 
CAC, cardiovascular risk factors and CAD may have not 
been detected. To achieve a sufficient event rate for our 
pilot study, we concentrated on this high-risk population. 
This also explains why conventional risks factors could 
not be used for further risk stratification in this popula-
tion. The data of our pilot work have to be confirmed by 
larger studies in asymptomatic patients.
 Although the CAC score combined with PAT volume 
offers the possibility of improved risk stratification, the 
clinical benefit is limited in the study population, as all 
patients are already eligible for secondary prevention. 
Again, the clinical relevance has to be evaluated in a larg-
er asymptomatic population.
 Due to the fact that vascular segments with stents were 
excluded from analysis, we may have slightly underesti-
mated the CAC score in these patients. However, as the 
segments with stents represent only a small portion of the 
whole coronary system, this possible consequent under-
estimation of the CAC score should be minimal.
 Conclusions 
 The findings of our study identify PAT as a risk marker 
for future cardiovascular events in addition to CAC. By us-
ing the data of a CT data set for CAC screening, this local 
fat depot can be easily quantified with a high reproducibil-
ity. However, future prospective trials are needed to con-
firm the supportive power of this parameter. In addition, 
it remains to be evaluated whether the identified patients 
at risk can profit from a prophylactic medical treatment.
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